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PsychosisThe study aimed to determine the clinical and neuropsychological predictors of responsiveness to cognitive
behavioural therapy for psychosis (CBTp). Sixty patients with schizophrenia or schizoaffective disorder and
25 healthy individuals took part in the study. Thirty patients (25 protocol completers) received CBTp in
addition to standard care (SC); 30 patients (18 protocol completers) received SC only. All patients were
assessed on symptoms using the Positive and Negative Syndrome Scale (PANSS) and clinical and
neuropsychological function before and after CBTp. Symptoms and self-esteem improved to a greater extent
in the CBTp+SC than SC control group. Greater pre-therapy coping ability and the self-reﬂectiveness
dimension of cognitive insight at baseline predicted improvement in symptoms in the CBTp+SC group, but
not the SC control group, explaining up to 21% of the variance in symptom improvement. Pre-therapy
neuropsychological function, duration of illness, clinical insight and gender did not predict CBTp
responsiveness. Being able to have a range of coping strategies and reﬂect on one's experiences while
refraining from overconﬁdence in one's interpretations before therapy is conducive to better CBTp
responsiveness.O78, Institute of Psychiatry, De
5102; fax: +44 207 848 0860.
. Premkumar).
er CC BY license.© 2010 Elsevier Ireland Ltd. Open access under CC BY license.1. Introduction
The extent to which neuropsychological and clinical factors
determine responsiveness to cognitive behavioural therapy (CBT)
for individuals with a psychotic disorder remains unclear. Seven
randomised controlled trials (RCTs) have examined the clinical
predictors of CBT for psychosis (CBTp) (Tarrier et al., 1993; Garety
et al., 1997; Tarrier et al., 1998; Naeem et al., 2008; Brabban et al.,
2009; Emmerson et al., 2009; Perivoliotis et al., 2010) (see
Supplementary data for a summary of the studies), but have yielded
somewhat contradictory ﬁndings.
Tarrier et al. (1993) found that greater pre-therapy positive
symptom severity predicted greater positive symptom improvement
following CBTp. In contrast, Naeem et al. (2008) combined the
results of two relatively large RCTs of CBTp versus treatment as usual in
the Insight trial (N=422) and versus befriending in the London
Newcastle trial (N=90), and in the Insight trial, reported that lower
pre-therapy general psychopathology predicted the greater likelihood
of a good treatment outcome in the CBTp group, deﬁned as a 25%
improvement in general psychopathology, but not positive symptoms.Tarrier et al. (1998) found that the likelihood of a 50% improvement in
positive symptoms was predicted by a shorter duration of illness in
those receiving CBTp, but not in those receiving routine care or
supportive counselling, while Garety et al. (1997) did not ﬁnd relation-
ships between length of illness or age of onset and outcome, but
observed that having a greater number of admissions in the previous
ﬁve years was related to subsequent improvement in positive
symptoms. Brabban et al. (2009) reported that being female was
associated with a greater likelihood of improvement in general
psychopathology, while again Garety et al. (1997) did not.
There are, however, more consistent results showing that some
aspects of insight may be related to good outcome in CBTp. Both
Garety et al. (1997) and Brabban et al. (2009) showed that cognitive
ﬂexibility about delusions, i.e. acknowledging that another view of the
delusion may be possible, and having lesser conviction in one's
delusional beliefs, was associated with a greater likelihood of
improvement. Naeem et al. (2008) found that better pre-therapy
insight into ‘illness’ predicted good outcome in the Insight study.
Emmerson et al. (2009) found that greater clinical insight [awareness
that the patient has a mental illness or speciﬁc symptoms, awareness
of need for treatment, and attribution of symptoms to mental illness,
as assessed by the Birchwood Insight Scale (BIS, Birchwood et al.,
1994)] at baseline predicted greater improvement in independent
living skills following CBTp, while Perivoliotis et al. (2010) reported
that greater cognitive insight (the patient's ability to reﬂect on his/her
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particular self-reﬂectiveness (Beck Cognitive Insight scale, BCI, Beck
et al., 2004), was associated with an improvement in severity of
delusions and auditory hallucinations. While the Garety et al. (1997)
study did not ﬁnd that clinical or illness insight was predictive of good
outcome, insight into the social consequences of one's illness
predicted improvements in the CBTp group.
Neuropsychological ability in the form of general intelligence or
speciﬁc neuropsychological functions, such as memory, attention and
executive function, may also play an important role in the therapeutic
success of CBT. Neuropsychological impairment in individuals
receiving therapy for alcohol dependence, for example, can impede
acquisition of new coping behaviours (McCrady and Smith, 1986) or
learning and retention of new material (Alterman and Hall, 1989).
Three studies (Garety et al., 1997; Granholm et al., 2008; Penades
et al., 2010) (see Appendix A for a summary of the studies) examined
pre-therapy neuropsychological predictors of CBTp response in
patients with a schizophrenia or schizoaffective disorder diagnosis,
of which two studies (Garety et al., 1997; Penades et al., 2010)
targeted symptom improvement, while Granholm et al. (2008)
targeted dysfunctional performance beliefs that interfered with social
functioning. Penades et al. (2010) reported that schizophrenia
patients who showed a reliable improvement in symptoms had
greater pre-therapy verbal memory than non-improvers. Neither
Garety et al. (1997) nor Granholm et al. (2008) found that IQ or
neuropsychological performance were predictive of good outcome.
However, Garety et al. (1997) did not use a comprehensive
neuropsychological battery, while CBT in the Granholm et al. (2008)
study did not target symptom reduction.
One area which has not been investigated in CBTp outcome
research is coping style. Coping enhancement has formed a part of
some forms of CBTp (Tarrier et al., 1993; Tarrier et al., 1998; Andres
et al., 2003) and been associated with better therapeutic outcome
than standard care (SC) or supportive counselling. Patients' mastery
of active, problem-focused coping strategies immediately after com-
pletion of therapy is reported to predict better psychopathological and
social outcome 12–18 months after therapy (Andres et al., 2003). The
successful acquisition of coping strategies during therapy may be
dependent on an individual's pre-existing coping style, thereby
inﬂuencing therapeutic outcome. No study, to our knowledge, has
yet examined the role of pre-therapy coping styles in CBT respon-
siveness in psychosis.
The present study aimed to determine the pre-therapy clinical and
neuropsychological predictors of CBTp responsiveness in patients
with schizophrenia or schizoaffective disorder. Based on earlier
ﬁndings and the literature about the role of coping in CBTp, we
tentatively hypothesized that a shorter duration of illness, better
cognitive insight, more active coping, greater verbal memory and
cognitive ﬂexibility at baseline would be associated with better CBTp
responsiveness, as measured by signiﬁcant clinical improvement on
the Positive and Negative Syndrome Scale (PANSS, Kay et al., 1987).
The study also examined the change in clinical status and neuropsy-
chological function following CBTp. It was hypothesized that
symptoms and cognitive insight would improve following CBTp,
since improvement in symptoms was associated with greater post-
therapy cognitive insight in two previous studies (Granholm et al.,
2002; Perivoliotis et al., 2010).2. Methods
2.1. Participants and design
Participants were 60 outpatients with a DSM-IV diagnosis of schizophrenia or
schizoaffective disorderwhowerewilling to receive CBTp in addition to their usual care.
Twenty-ﬁve healthy participants were also included in order to characterize the patient
group. The patient and healthy participant groupswerematched on average for age and
sex. Data on the improvement of symptoms in the CBTp+SC group compared to SCcontrol group following CBTp have been reported in our recent reports on the functional
MRI predictors (Kumari et al., 2009; Kumari et al., 2010) and structuralMRI predictors of
CBTp responsiveness (Premkumar et al., 2009). Thirty patients received CBTp+SC (25
protocol completers) and 30 patients received SC (18 protocol completers in this part of
the study). Thereweremore drop-outs in the SC control group than the CBTp+SC group
(Chi-square=4.022, p=0.045). Of those recruited to the CBTp+SC group, ﬁve patients
left the study early (one patient discontinued therapy and four patients withdrew
consent). Of those recruited to the SC control group, 12 patients dropped out (ﬁve
patients withdrew consent; ﬁve patients did not undergo baseline MRI and were not
followed-up, one patient moved to another area and could not be contacted, and one
patient was incarcerated during the period of his scheduled follow-up). The ﬁve CBTp+
SC non-completers did not differ from the CBTp+SC completers on pre-therapy clinical
status and neuropsychological function, whereas SC control non-completers had lower
pre-therapy scores on 2 out of 12 neuropsychological measures than SC control
completers (Letter-Number test number of items correctly recalled: completers=13.22
(2.58) and non-completers=9.30 (4.37), F=9.01, df=1,25, p=0.006; Hopkins verbal
learning test number of items freely recalled: completers=22.39 (4.58) and non-
completers=17.78 (5.14), F=5.62, df=1,25, p=0.026). SC control completers and
non-completers did not differ on pre-therapy clinical status.
All patients received a PANSS rating≥60, reported at least one positive ‘distressing’
symptom of schizophrenia and wished to receive CBTp in addition to SC. Patients were
on stable doses of antipsychotic medication for at least two years and on the current
antipsychotic drug for at least three months prior to taking part (86% on atypical
antipsychotics). Patients in both treatment groups were recruited from the South
London and Maudsley (SLAM) NHS Foundation Trust, were identiﬁed by local
psychiatric consultants as suitable for CBTp and wished to receive CBTp in addition
to their usual care. Patients who were referred to and accepted for CBTp by the
Psychological Interventions Clinic for Outpatients with Psychosis (PICuP), SLAM NHS
Foundation Trust, went into the CBTp+SC group. Ninety-ﬁve patients were referred to
PICuP, of whom 31% participated in the study, 23% did not wish to take part, 21% were
not considered because they were either not ﬂuent English speakers or had received
CBTp in the past, 20% were not suitable for PICuP or withdrew before assessment of
suitability for PICuP, and 3% were not suitable for MRI; the reason for non-inclusion of
2% was not known (most likely they missed their appointment). Those who did not
wish to take part or were excluded had a similar age on average to those who took part.
Patients who matched the CBTp+SC group patients demographically and clinically as
much as possible were studied as part of the SC control group over the same interval as
the CBTp+SC group patients. Patients were recruited in a case-controlled manner.
Although treatment allocation was not randomised, there was no discernable
difference between CBTp+SC and SC control groups with regard to their suitability
or desire to undergo the intervention.
CBTp was delivered by trained therapists, and followed the procedure developed
by Fowler et al. (1995). CBTp, as deﬁned by the National Institute for Health and Clinical
Excellence updated guidelines (NICE, 2009), consisted of enabling the patient to: (i)
establish links between their thoughts, feelings or actions with respect to the current or
past symptoms, and/or functioning; and (ii) re-evaluate their perceptions, beliefs or
reasoning related to the target symptoms. In addition, CBTp involved enabling the
patient to monitor his/her own thoughts, feelings or behaviours with respect to
the symptom or recurrence of symptoms; and/or (i) promotion of alternative ways
of coping with the target symptom, (ii) the reduction of distress, and/or (iii)
the improvement of functioning. Therapy sessions were conducted on a weekly
or fortnightly basis, as preferred by the patient. CBTp patients received an average of 19
(S.D. 7) therapy sessions. Treatment adherence was assessed by fortnightly
supervision. In addition, a number of therapy sessions (n=13) were taped and rated
independently by an experienced CBTp therapist for ﬁdelity of treatment using the
Cognitive Therapy Scale for Psychosis (Haddock et al., 2001). The mean rating was 40.7
(range 21–53) out of a maximum of 60, with 77% of the tapes scoring above the 50%
mark (i.e. rating score N30).
SC consisted of case management offered by the case management team for a
particular geographical area. The case management included regular reviews with a
dedicated care coordinator who monitored the patient's mental health needs, offered
support and provided further specialist input, viz. regular reviews with a psychiatrist.
The care coordinator also arranged for support from other specialists, such as a
psychologist, vocational adviser, beneﬁts adviser and occupational therapist as needed.
Six-monthly care plan assessment reviews were carried out with a focus on recovery.
The patients in the SC control group were not receiving any control psychological
intervention.
The study procedures were approved by the ethics committee of the Institute of
Psychiatry and the SLAM NHS Foundation Trust, London. All participants provided
written informed consent to their participation andwere compensated for their time in
undergoing MRI scanning and clinical and neuropsychological assessments (partici-
pants were not paid for therapy) and travel.
2.2. Clinical assessments
Clinical diagnosis at baseline was conﬁrmed by a consultant psychiatrist (DF) using
the Structured Clinical Interview for DSM-IV (First et al., 2002). PANSS assessments
(Kay et al., 1987) were performed on patients before and after CBTp by an experienced
psychiatrist (DF). This psychiatrist played no role in patient recruitment or clinical
management of the patients included in this investigation and was blind to whether or
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neuropsychological assessments were carried out by doctoral-level researchers on
patients at baseline and follow-up. Neuropsychological assessments in healthy
participants were performed once (at baseline).
2.2.1. Beck Depression Inventory-II
The Beck Depression Inventory-II (Beck, 1996) is a 21-item questionnaire assessing
the main emotional, cognitive and physiological symptoms of depression (Beck et al.,
1988b). The total score was used in the analysis.
2.2.2. Beck Anxiety Inventory
The Beck Anxiety Inventory (Beck et al., 1988a) is a 21-item questionnaire
assessing the main symptoms associated with anxiety disorder. The total score was
used in the analysis.
2.2.3. Rosenberg Self-esteem Scale
The Rosenberg Self-esteem Scale (Rosenberg, 1965) is a 10-item self-reported
inventory. It measures overall feelings of self-worth or self-acceptance. Items are rated
on a 4-point Likert Scale from ‘Strongly Agree’ to ‘Strongly Disagree’. The total score was
used in the analysis.
2.2.4. Beck Cognitive Insight scale
The Beck Cognitive Insight scale (Beck et al., 2004) is a 15-item self-reported
inventory. The items separate into two factors, namely self-certainty and self-
reﬂectiveness. These two factors and the composite score, which is derived from the
difference between self-certainty and self-reﬂectiveness, were used in the analysis.
2.2.5. Schedule for the Assessment of Insight — expanded
The Schedule for the Assessment of Insight — expanded (SAI-E) (Kemp and David,
1997) is a 9-item researcher administered inventory relating to the patient's awareness
of illness and speciﬁc symptoms, illness attribution, awareness of illness consequences,
treatment compliance, symptom re-labelling, and openness to contradiction of his/her
beliefs. The total score was used in the analysis.
2.2.6. Birchwood Insight Scale
The BIS (Birchwood et al., 1994) is an 8-item self-reported inventory. Items include
“Some of my symptoms are made by my mind” and “The doctor is right in prescribing
medication for me”. Item 4 “My stay in hospital is necessary” was disregarded, as all
patients were outpatient. The total score was used in the analysis.
2.2.7. Coping Orientation to Problems Experience
The Coping Orientation to Problems Experienced (COPE) inventory (Carver et al.,
1989) is a 60-item self-reported coping inventory which assesses the ways in which
individuals respond to stress based on the theoretical principles underlying Lazarus'
model of stress (Lazarus, 1966; Lazarus and Folkman, 1984). The format used in the
present study asked patients to indicate how they had been coping with the stress
in their life since they were told that they had a mental health problem. The scale
consists of 15 subscales, namely Positive reinterpretation and growth, Mental
disengagement, Focus on and venting of emotions, Use of instrumental social support,
Active coping, Denial, Religious coping, Behavioural disengagement, Restraint, Use of
emotional social support, Substance use, Suppression of competing activities,
Acceptance, Planning and Humour. The total and subscale scores were used in the
analysis.
2.3. Neuropsychological assessments
2.3.1. General intelligence
2.3.1.1. Wechsler Abbreviated Scale of Intelligence. The Wechsler Abbreviated Scale of
Intelligence (WASI, Wechsler, 1999) is designed to be a short test of general intellectual
ability. The two-subtest version of the WASI consists of the Vocabulary subtest and the
Matrix Reasoning subtest. The subtests were combined to estimate full-scale equivalent
current IQ.
2.3.1.2. National Adult Reading test. The National Adult Reading test (Nelson andWilson,
1991) is a measure of premorbid IQ. Selection of the word list in this test is based on the
existence of atypical words that do not follow the common rules of grapheme–
phoneme representation and pronunciation. Predicted premorbid IQ was the variable
used in the analysis.
2.3.2. Executive function
2.3.2.1. Behavioural Assessment of Dysexecutive Syndrome. The Behavioural Assessment
of Dysexecutive Syndrome (BADS, Wilson et al., 1996) is a test of executive functioning
comprising six subtests: Rule Shift Cards, Action Program Test, Temporal Judgement
Test, Key Search Test, Zoo Map Test, and the Modiﬁed Six Elements. Each subtest has a
range of scores from 0 to 4. Total proﬁle score was the variable used in the analysis.
2.3.2.2. Brixton Spatial Anticipation test. The Brixton Spatial Anticipation test (BSAT,
Burgess and Shallice, 1997) is a test of concept formation in which the participant ispresented with a sequence of 56 near-identical stimuli, each of which has 10 circles,
one of which is coloured blue. The participant is instructed to point to the expected
position of a coloured circle on the next page. The location of this coloured circle is
determined by one of nine rules based on the previous position of the coloured circle.
The number of perseverative errors was used in the analysis.
2.3.2.3. Wisconsin Card Sorting test. The computerised version of the Wisconsin Card
Sorting test (WCST, Heaton et al., 1993) was used. Participants are asked to match the
choice-card to the upper panel of cards using a hidden rule. Successful completion of
the WCST requires participants to (a) attain concept or the current rule, (b) maintain
the concept for 10 consecutive trials and (c) switch the concept when the sorting rule is
changed. Number of perseverative errors was used in the analysis.
2.3.3. Working memory
2.3.3.1. Letter Number test. In this task (Gold et al., 1997), participants are asked to recall
a string of letters and numbers, placing the numbers ﬁrst in ascending order, followed
by the letters in alphabetical order. Total number of correct items was used in the
analysis.
2.3.4. Immediate verbal learning and memory
2.3.4.1. Wechsler Memory Scale III — Logical Memory. In this subtest of the Wechsler
Memory Scale — III (Wechsler, 1998), the participant listens to two different stories
read by the examiner and is asked to retell it from memory immediately after hearing
each story (immediate recall) and half an hour later (delayed recall). Immediate and
delayed unit recall scaled scores were used in the analysis.
2.3.4.2. Hopkins Verbal Learning test — Revised. In the free recall part of the Hopkins
Verbal Learning test (Shapiro et al., 1999), the examiner reads out a list of 12 words
which the participant is asked to recall. The list is read out three times and the number
of words correctly recalled on each occasion is noted. Total number of items freely
recalled was used in the analysis.
2.3.5. Attention
2.3.5.1. Continuous Performance Test — Identical Pairs (CPT-IP). This test (Cornblatt et al.,
1988) requires the participant to respond when two identical stimuli appear
consecutively on the computer screen. Stimuli (four-digit numbers) are ﬂashed on
the screen at a constant rate of one stimulus per second, with a stimulus “on” time of
50 ms. Target trials are the second stimulus of a pair of identical stimuli.
Discriminability index was used in the analysis.
2.3.6. Verbal skills
2.3.6.1. Verbal ﬂuency test. The verbal ﬂuency test (Milner, 1975) requires the
participant to generate as many words as possible starting with a speciﬁed letter or a
speciﬁed category within 60 seconds. Word generation is based on one of three letters:
F, A and S, and on one of three categories: animal, fruit and vegetable. Number of
correct words generated in each subtest was used in the analysis.
2.3.7. Cognitive inhibition
2.3.7.1. Hayling Sentence Completion Test. The Hayling Sentence Completion Test (HSCT,
Burgess and Shallice, 1997) requires the participant to provide single-word comple-
tions to sentences, each of which has the last word missing. There are two parts: in part
A, participants must produce sensible completions as quickly as possible; in part B, the
participant must produce completions that are unrelated to the preceding sentence.
The time taken to complete the two parts as well as the errors made in part B is
converted into a scaled score. Hayling B scaled score was used in the analysis.
2.3.8. Emotional decision-making
2.3.8.1. Iowa Gambling Task. In the Iowa Gambling Task (IGT) (Bechara et al., 1994),
participants choose cards from advantageous and disadvantageous decks, such that
choosing from the disadvantageous decks is associated with greater immediate
monetary reward compared to the advantageous decks, but an overall greater
monetary loss compared to the advantageous decks. The trials are presented in ﬁve
blocks. Overall learning (score on Block 5 minus Block 1) was used in the analysis.
2.4. Statistical analysis
2.4.1. Comparison of patient group characteristics at baseline
Due to the large number of neuropsychological measures (n=12), individual test
scores were combined within each domain to provide composite domain scores at
baseline and follow-up (see Section 2.3 neuropsychological assessments for tests
included in each domain) based on the approach followed by Kern et al. (2008). The
patient groups were compared on gender using Chi-squared test, and baseline clinical
and neuropsychological domain variables using analysis of variance or Mann–Whitney
U-tests for variables with signiﬁcant heterogeneity of variance (number of years in
2 The following COPE subscales correlated positively with improvement in total
symptoms in the CBTp+SC group: active coping (Spearman's rho=0.657, p=0.001),
suppression of competing activities (rho=0.485, p=0.026) and acceptance
(rho=0.440, p=0.046). The following COPE subscales correlated positively with
improvement in negative symptoms: planning (rho=0.596, p=0.004), active coping
(rho=0.473, p=0.030) and use of emotional social support (rho=0.465, p=0.034).
The following COPE subscales correlated positively with improvement in general
psychopathology symptoms: planning (rho=0.671, p=0.001), active coping
(rho=0.498, p=0.022) and suppression of competing activities (rho=0.489,
p=0.024). Behavioural disengagement correlated negatively with improvement in
general psychopathology symptoms (rho=−0.430, p=0.052).
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verbal skills and emotional decision-making domain scores).
2.4.2. Change in clinical status and neuropsychological ability from baseline to follow-up
Absolute change from baseline to follow-up was computed for each clinical and
neuropsychological domain variable (calculated so that a negative change score
indicated improvement in clinical status or neuropsychological function at follow-up).
For all clinical measures (except BCI composite index subscale), a higher score on the
scale indicates greater severity. Therefore, change on these clinical measures was
calculated as follow-up score minus baseline score (except for BCI composite index
subscale, where change was calculated as baseline score minus follow-up score). For all
neuropsychological domain scores, a higher score indicates better performance.
Therefore, change on neuropsychological domain scores was calculated as baseline
score minus follow-up score. Analyses of co-variance were carried out in order to
compare the change in clinical and neuropsychological domain scores in the two
patient groups with baseline clinical or neuropsychological domain score as the
covariate. For variables with signiﬁcant heterogeneity of variance in the change scores
between patient groups (verbal skills), Mann–Whitney U tests were performed.
2.4.3. Pre-therapy clinical predictors of symptom change
Analysis of variance with gender as the independent variable and residual change
in PANSS total, positive, negative and general psychopathology symptom ratings as the
dependent variable was performed in the CBTp+SC group. For the purpose of this
analysis, symptom change was estimated as the residual change in PANSS symptoms
(change in symptom scores covarying for baseline symptom scores) (Siegle et al.,
2006). Although other variables were also found to have changed signiﬁcantly at
follow-up (Results, Section 3.2 ‘Change in clinical status and neuropsychological ability
following CBTp’), given the modest sample sizes we limited our analyses to predictors
of psychotic symptom change. Pearson correlations, or Spearman correlations for
variables with signiﬁcant kurtosis or skewness (antipsychotic medication level and
Birchwood Insight total score), were performed between pre-therapy clinical variables
and symptom change scores in the CBTp+SC and SC control groups separately. In order
to determine whether the pre-therapy clinical variables found to signiﬁcantly predict
CBTp responsiveness had a differential effect on outcome in the CBTp+SC relative to SC
control group, correlations were repeated in the SC control group for those correlations
found to be signiﬁcant in the CBTp+SC group. The correlation coefﬁcients from the two
groups were compared using Fisher's z transformation (Howell, 2002).
Finally, Pearson correlations were performed between number of CBTp therapy
sessions and symptom change scores in order to examine whether this factor was
related to treatment outcome.
As the aforementioned correlational analyses showed that pre-therapy COPE total,
BCI self-reﬂectiveness and BCI composite index scores correlated with symptom
change following CBTp (Results, Section 3.3), multiple regression analyses were
performed to determine which pre-therapy clinical variable contributed more strongly
to the variance in the criterion variable (symptom change) in the CBTp+SC group.
Predictor variables (pre-therapy COPE total, BCI self-reﬂectiveness and BCI composite
index scores) were entered in a stepwise manner (to estimate the effect of individual
predictors on the variability of the criterion variable) and using a standard regression
(all predictors were entered simultaneously and results were given for only one step to
explain the combined effect of predictors on the variability of the criterion variable).
2.4.4. Pre-therapy neuropsychological correlates of symptom change
Pearson correlations were performed between pre-therapy neuropsychological
domain scores and symptom change scores following CBTp in CBTp+SC patients.
All analyses were performed in SPSS (version 15). Alpha level for testing
signiﬁcance of effects was maintained at p≤0.05.
3. Results
3.1. Characteristics of patient groups at baseline
The CBTp+SC group had lower BCI self-certainty, greater BCI
composite index, and greater SAI total scores than the SC control
group at baseline (see Table 1). The CBTp+SC group had higher
general IQ and verbal skills and tended to have better attention than
the SC control group at baseline (see Table 1 and Fig. 1).
3.2. Change in clinical status and neuropsychological ability following
CBTp
The CBTp+SC group showed greater improvement from baseline
to follow-up than the SC control group on total, positive, negative and
general psychopathology symptom ratings, as well as self-reported
depression and self-esteem, with a trend towards improvement in BCI
self-certainty (lower self-certainty) (see Table 2).There were no signiﬁcant differences in outcome between the
groups on anxiety, clinical insight and BCI composite index, coping
skills, or any of the neuropsychological domains (see Table 2).3.3. Pre-therapy clinical and neuropsychological predictors of CBTp
responsiveness
Therewas no effect of gender on symptom change in the CBTp+SC
group (total symptoms change, F=0.241, df=1,11, p=0.632;
positive symptoms change, Fb0.001, df=1,11, p=0.990; negative
symptoms change, F=0.151, df=1,11, p=0.700; general psychopa-
thology change, F=1.593, df=1,11, p=0.233).
Greater BCI self-reﬂectiveness scores at baseline correlated with
improvement in total symptom ratings in the CBTp+SC group
(r=0.409, p=0.042), but not the SC control group (r=−0.180,
p=0.475) (see Table 3). These correlation coefﬁcients differed
between groups (z=1.845, p=0.033). Greater BCI self-reﬂectiveness
at baseline also correlated with improvement in negative symptoms
in the CBTp+SC group (r=0.419, p=0.037), but not the SC control
group (r=−0.054, p=0.831). These correlation coefﬁcients differed
between groups at a trend level (z=1.487, p=0.068).
Greater BCI composite scores at baseline correlated with improve-
ment in total symptoms in the CBTp+SC group (r=0.419, p=0.037),
but not in the SC control group (r=−0.227, p=0.364). These
correlation coefﬁcients differed between groups (z=2.022,
p=0.020). Greater BCI composite scores at baseline also correlated
with improvement in general psychopathology symptoms in the
CBTp+SC group (r=0.426, p=0.034), but not in the SC control
group (r=−0.155, p=0.540). Again, these correlation coefﬁcients
differed between groups (z=1.822, p=0.030).
Greater coping ability at baseline correlated with improvement in
total symptoms in the CBTp+SC group (r=0.496, p=0.022), but not
in the SC control group (r=0.043, p=0.874).2 These correlation
coefﬁcients differed between groups at a trend level (z=1.382,
p=0.085). Greater coping ability at baseline also correlated with
improvement in negative symptoms in the CBTp+SC group
(r=0.450, p=0.041), but not in the SC control group (r=−0.056,
p=0.838). These correlation coefﬁcients differed between groups at a
trend level (z=1.4842, p=0.069). Lastly, greater coping ability at
baseline correlated with improvement in general psychopathology
symptoms in the CBTp+SC group (r=0.424, p=0.055), but not in
the SC control group (r=0.168, p=0.533). These correlation
coefﬁcients did not differ between groups (z=0.788, p=0.215).
In the CBTp+SC group, there were no signiﬁcant correlations
between symptom change from baseline to follow-up and illness
duration, age of onset, level of antipsychotic medication, self-reported
depression and anxiety, clinical insight, self-esteem, BCI self-certainty,
number of therapy sessions and any of the neuropsychological
domains at baseline (see Table 3).
A stepwise multiple regression (stepwise model: multiple
R=0.496, F=6.215, p=0.022) of pre-therapy COPE total, BCI self-
reﬂectiveness and BCI composite index scores on total symptom
change scores in the CBTp+SC group revealed that COPE total was a
signiﬁcant predictor and explained 20.7% of the variance in total
symptom change. Together (standard regression model: multiple
Table 1
Clinical and neuropsychological characteristics at baseline in CBTp+SC and SC control groups.
CBTp+SC (n=25) SC control (n=18) F or Z† Statistic df p
N Mean S.D. N Mean S.D.
Characteristic
Gender (number of males/females) 25 17/8 18 15/3
Age 25 36.08 8.02 18 39.72 10.49 F 1.688 1,41 0.204
Years in education 25 14.04 2.91 18 13.28 1.93 Z 0.696 1,41 0.487
Duration of illness 25 11.73 7.89 18 14.50 12.10 Z 0.444 1,41 0.657
Age of onset 25 24.36 8.01 18 25.22 8.24 F 0.188 1,41 0.733
Medication dosage— CPZ equivalent 25 526.15 385.78 18 459.65 336.47 F 0.345 1,41 0.560
PANSS symptoms at baseline
Positive 25 17.96 4.74 18 18.33 3.45 F 0.081 1,41 0.778
Negative 25 17.84 4.36 18 19.05 3.89 F 0.888 1,41 0.352
General psychopathology 25 32.72 7.21 18 35.50 4.19 F 2.146 1,41 0.151
Total 25 68.52 13.53 18 72.89 9.01 F 1.417 1,41 0.241
BDI 24 15.75 8.29 18 16.44 10.18 F 0.059 1,40 0.809
BAI 25 14.16 10.81 18 20.06 12.20 F 2.795 1,41 0.102
Rosenberg self-esteem 25 23.88 6.24 17 23.18 5.68 F 0.138 1,40 0.712
BCI self-reﬂectiveness 25 16.28 5.81 18 13.44 5.40 F 2.643 1,41 0.112
BCI self-certainty 25 5.84 3.58 18 8.44 3.60 F 5.514 1,41 0.024
BCI composite 25 10.44 7.17 18 5.00 7.04 F 6.122 1,41 0.018
SAI total 24 13.18 5.88 17 10.61 5.24 F 4.767 1,39 0.035
Birchwood insight total 25 9.68 2.14 18 5.17 2.12 Z 1.796 1,41 0.072
COPE total 21 73.86 28.15 16 82.87 29.75 F 0.888 1,35 0.353
Neuropsychological domain
General intelligence 25 41.13 12.31 18 32.75 14.88 F 4.074 1,41 0.050
Executive function 25 38.63 19.60 18 31.45 10.86 F 1.968 1,41 0.168
Working memory 25 42.21 12.55 18 39.49 8.19 Z 0.496 1,41 0.620
Immediate verbal learning and memory 25 36.12 9.18 18 35.98 8.78 F 0.003 1,41 0.959
Attention 25 42.54 8.48 18 37.91 6.75 F 3.681 1,41 0.062
Verbal skills 25 44.01 8.64 18 37.40 5.75 Z 2.511 1,41 0.012
Cognitive inhibition 25 46.03 11.99 18 42.04 13.95 F 1.014 1,41 0.320
Emotional decision-making 25 45.82 13.08 18 44.11 8.73 Z b0.001 1,41 1.000
Values in bold: signiﬁcant difference between patient groups at p≤0.05; †Mann–Whitney U test (Z statistic) performed for variables with signiﬁcant variance heterogeneity between
groups.
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predictors together explained 21.6% of the variance in total symptom
change.
A stepwise multiple regression (stepwise model: multiple
R=0.450, F=4.828, p=0.041) of pre-therapy COPE total and BCI
self-reﬂectiveness scores on negative symptom change scores in the
CBTp+SC group revealed that COPE total was a signiﬁcant predictor
and explained 16.1% of the variance in negative symptom change.Fig. 1. Pre-therapy standardized T-scores of neuropsychological domains in CBTp+SC
(n=25), SC control (n=18) and healthy participant groups (n ranging from 19 to 25 in
different domains).Together (standard regression model: multiple R=0.521, F=3.359,
p=0.058), the two pre-therapy clinical predictors explained 19.1% of
the variance in negative symptom change.
The standard, but not the stepwise, multiple regression of pre-
therapy COPE total and BCI composite scores on general psychopa-
thology symptom change in the CBTp+SC group was signiﬁcant
(multiple R=0.532, F=3.550, p=0.050). Pre-therapy COPE total and
BCI composite index scores together explained 20.3% of the variance
in general psychopathology severity change.
4. Discussion
The present study investigated (a) the pre-therapy clinical and
neuropsychological predictors of CBTp and (b) the change in clinical
status and neuropsychological function following CBTp. The ﬁndings
from these investigations will be discussed in turn.
4.1. Clinical and neuropsychological predictors of CBTp responsiveness
Three pre-therapy clinical variables emerged as signiﬁcantpredictors
of total symptom improvement following CBTp, namely coping, and two
out of the three Cognitive Insight Scale (Beck et al., 2004) scores, namely
self-reﬂectiveness and the composite index score (being able to self-
reﬂect while refraining from overconﬁdence in one's judgements). Pre-
therapy cognitive insight and coping predicted symptom improvement
more strongly in the CBTp+SC than the SC control group, suggesting
that they are speciﬁc predictors of CBTp responsiveness rather than of
good outcome in general, although the size of the difference in the
coping-symptom change relation between the CBTp and SC control
groupswasweaker than the cognitive insight-symptomchange relation.
Therefore, coping and cognitive insight (participants' intrinsic ability to
Table 2
Change in clinical and neuropsychological status from baseline to follow-up in CBTp+SC and SC control groups controlling for clinical status at baseline.
CBTp+SC SC control F or Z† Statistic p
N Mean S.D. N Mean S.D.
Clinical variable
PANSS symptoms
Positive 25 −3.04 4.05 18 −0.56 3.79 F 6.246 0.017
Negative 25 −2.36 3.81 18 0.72 4.67 F 9.551 0.004
General psychopathology 25 −4.68 7.42 18 −0.83 6.70 F 6.772 0.013
Total symptoms 25 −10.08 12.93 18 −0.67 12.19 F 8.664 0.005
BDI 23 −5.57 10.17 17 0.76 7.50 F 4.775 0.035
BAI 23 −4.26 10.71 17 −3.18 12.61 F 2.864 0.099
Rosenberg self-esteem 25 −1.04 6.15 17 2.25 3.84 F 4.069 0.051
BCI self-reﬂectiveness 25 −1.48 4.69 16 b−0.001 4.26 F 0.045 0.833
BCI self-certainty 25 −1.52 3.87 16 −0.37 3.67 F 3.791 0.059
BCI composite 25 0.04 3.55 17 0.37 6.16 F 0.398 0.532
SAI total‡ 14 0.89 5.46 9 2.63 3.61 F 0.710 0.409
Birchwood insight total 25 −0.27 1.80 16 −0.27 1.87 F 0.244 0.624
COPE total 21 −2.00 27.28 13 −0.77 20.55 F 0.531 0.472
Neuropsychological domain
Executive function 18 −2.40 16.57 13 −7.83 12.98 F 0.494 0.488
Working memory 24 −2.82 10.10 17 −1.81 7.46 F 0.681 0.414
Immediate verbal learning and memory 25 −5.55 7.75 17 −3.23 7.50 F 1.160 0.288
Attention 24 −1.30 7.55 17 −2.68 7.94 F 0.033 0.856
Verbal skills 24 −1.28 5.13 17 −1.19 3.25 Z 0.132 0.895
Cognitive inhibition 24 −2.22 11.94 17 −1.39 20.66 F 0.535 0.469
Emotional decision-making 23 −0.35 16.42 17 1.82 11.83 F 2.288 0.139
Values in bold: signiﬁcant difference between patient groups at p≤0.05; negativemean score indicates improvement in clinical or neuropsychological status; †Mann–Whitney U test
(Z statistic) performed for variables with signiﬁcant variance heterogeneity between groups; ‡SAI total score at follow-up was available only for patients who had a score ≥4 on a
PANSS positive item.
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illness, gender or neuropsychological function, appeared to be the
important factors in predicting symptom improvement following CBTp.
However, these relationships were signiﬁcant for negative and general,
but not positive, symptom improvement.
Pre-therapy coping was found to be the strongest of the three
signiﬁcant predictors of change. Several pre-therapy coping strategies
were associated with CBTp responsiveness (e.g. active coping,
planning and use of emotional social support). The pattern of our
ﬁndings is consistent with the view that patients with schizophrenia
who have a range of coping strategies and are ﬂexible about theirTable 3
Correlation between baseline clinical status/neuropsychological function and symptom cha
N PANSS total
Baseline clinical variable
Duration of illness 25 −0.066 (0.753)
Age of onset 25 0.380 (0.061)
†Medication dosage (CPZ equivalent) 25 0.019 (0.929)
BDI 24 0.179 (0.402)
BAI 25 0.077 (0.716)
Rosenberg Self-Esteem 25 0.176 (0.399)
BCI self-reﬂectiveness 25 0.409 (0.042)
BCI self-certainty 25 −0.175 (0.401)
BCI composite 25 0.419 (0.037)
SAI total 24 0.094 (0.663)
†Birchwood insight total 25 −0.176 (0.401)
COPE total 21 0.496 (0.022)
Number of therapy sessions 22 −0.116 (0.608)
Neuropsychological domain
General intelligence 25 −0.385 (0.057)
Executive function 25 −0.006 (0.976)
Working memory 25 −0.176 (0.401)
Immediate verbal learning and memory 25 −0.120 (0.569)
Attention 25 −0.290 (0.159)
Verbal skills 25 −0.055 (0.793)
Cognitive inhibition 25 −0.213 (0.306)
Emotional decision-making 25 0.168 (0.422)
Values in bold: signiﬁcant correlation at p≤0.05; †Spearman's rho correlation performed focoping responses are more likely to experience psychological well-
being (Phillips et al., 2009). Active coping is the process of taking
active steps to try to remove or circumvent the stressor or ameliorate
its effects (Carver et al., 1989). Active coping includes initiating direct
action, increasing one's efforts and trying to execute a coping attempt
in stepwise fashion (Carver et al., 1989). Planning is thinking about
how to cope with a stressor. Planning involves coming up with action
strategies, thinking about what steps to take and how best to handle
the problem. Being able to plan a coping response and then actively
carry out the response may moderate CBTp's aim to alleviate general
distress (i.e. reduce general symptoms) and increase functioning (i.e.nge in CBTp+SC patients.
PANSS positive PANSS negative PANSS general psychopathology
−0.092 (0.661) −0.096 (0.647) −0.047 (0.823)
0.305 (0.139) 0.247 (0.235) 0.379 (0.062)
−0.152 (0.469) 0.329 (0.109) 0.075 (0.722)
0.087 (0.685) 0.338 (0.107) 0.122 (0.569)
0.062 (0.768) 0.026 (0.902) −0.007 (0.975)
0.068 (0.747) 0.371 (0.068) 0.113 (0.592)
0.210 (0.313) 0.419 (0.037) 0.376 (0.064)
−0.240 (0.247) −0.009 (0.966) −0.244 (0.240)
0.290 (0.159) 0.344 (0.092) 0.426 (0.034)
0.316 (0.132) −0.080 (0.711) 0.063 (0.771)
0.263 (0.204) −0.134 (0.524) −0.150 (0.475)
0.378 (0.091) 0.450 (0.041) 0.424 (0.055)
−0.137 (0.543) 0.083 (0.715) −0.200 (0.373)
−0.318 (0.121) −0.326 (0.112) −0.333 (0.104)
0.017 (0.934) −0.057 (0.788) 0.015 (0.945)
−0.248 (0.233) −0.104 (0.621) −0.171 (0.413)
−0.125 (0.550) 0.048 (0.820) −0.170 (0.415)
−0.339 (0.097) −0.185 (0.375) −0.231 (0.266)
0.007 (0.973) −0.081 (0.700) −0.012 (0.954)
−0.082 (0.698) −0.189 (0.366) −0.289 (0.161)
0.179 (0.393) 0.185 (0.377) 0.150 (0.473)
r this variable.
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to outcome for positive symptoms.
4.1.1. Insight and CBTp responsiveness
The ability to reﬂect on one's anomalous experiences (self-
reﬂectiveness) before therapy predicted improvement in negative
symptoms in the CBTp+SC, but not the SC control, group. Being able
to self-reﬂect while refraining from overconﬁdence in one's judge-
ments (composite index) before therapy predicted improvement in
general psychopathology in the CBTp+SC group, but not the SC
control group. These ﬁndings support and extend those of Perivoliotis
et al. (2010) and Garety et al. (1997) by demonstrating that cognitive
insight or ﬂexibility may be related to improvements in negative and
general symptoms. Having some ability to re-evaluate perceptions,
beliefs and reasoning beforehand may therefore beneﬁt CBTp
responsiveness in a number of different areas. Greater self-reﬂective-
ness is associated with lower severity of positive and negative
symptoms (Bora et al., 2007). In the present study, overconﬁdence
about one's interpretations per se did not predict symptom improve-
ment. This lack of a relationshipmay be because the level of delusional
beliefs in our group of patients before therapy may have been at a
moderate level, and overconﬁdence about judgements, which may be
equivalent to the jumping-to-conclusions (JTC) reasoning style, is
thought to underlie delusional beliefs (Garety and Freeman, 1999). In
one study (Warman and Martin, 2006), patients with schizophrenia
or schizoaffective disorder who had active delusions tended to
endorse their beliefs and judgements more readily than healthy
participants who were delusion-prone and healthy participants with
no delusional proneness, i.e. the patients with active delusions
expressed more conﬁdence in their judgements about the emotional
salience of personally relevant statements. Brabban et al. (2009)
found that a lower level of conviction about delusions predicted a
greater likelihood of improvement in general psychopathology only in
patients with delusions. The present study and an earlier study
(Perivoliotis et al., 2010) suggest that the composite index is different
conceptually from the individual subscales and shed light on the
nature of the Cognitive Insight scale. The results suggest that
refraining from overconﬁdence in one's judgements on its own does
not predict symptom improvement, but does in the context of being
able to self-reﬂect. The composite index takes into account the fact
that the two subscales are not mutually exclusive (Beck et al., 2004;
Warman et al., 2007).
In the multiple regression analyses of pre-therapy predictors of
CBTp responsiveness, pre-therapy cognitive insight did not add
signiﬁcantly to the variance of the model explained by pre-therapy
coping. This may have been because of the similar processes
involved in coping and cognitive insight, as suggested by the
overlapping variances of these variables. Clinical insight and coping
have already been shown to work congruently in alleviating
symptoms in patients with psychosis (Cooke et al., 2007; Lysaker
et al., 2005; Phillips et al., 2009). Those who are able to successfully
‘integrate’ their illness with their view of themselves are more likely
to develop successful coping strategies than those who ‘seal over’
and perceive their illness as negative and interrupting the progress
of their lives (Phillips et al., 2009). Cooke et al. (2007) observed a
range of associations between clinical insight and coping. Speciﬁ-
cally, better use of instrumental support and planning were
associated with better illness insight in schizophrenia patients,
and lesser mental disengagement and better ability to suppress
competing activities with better awareness of problem. Unlike
previous studies (Naeem et al., 2008; Emmerson et al., 2009), we
did not ﬁnd pre-therapy clinical insight to predict symptom
improvement following CBTp. However, the Insight trial (Naeem
et al., 2008) was speciﬁcally targeting insight as a treatment goal,
and Emmerson et al. (2009) were targeting independent living
skills, unlike the therapy delivered in this study, which was moresimilar to that implemented by Garety et al. (1997), who also did
not ﬁnd that clinical insight was a predictor of change.
In the present study, pre-therapy neuropsychological function-
ing did not predict CBTp responsiveness, which is mainly
consistent with previous studies (Garety et al., 1997; Penades et
al., 2010). Although Penades et al. (2010) reported verbal memory
to predict improvement in positive symptoms, their sample
comprised patients with a slightly longer duration of illness
[mean (S.D.)=14.9 (1.2)] than our sample [mean (S.D.)=11.73
(7.89)]. Penades et al. (2010) also used a categorical approach to
deﬁne whether patients were ‘improvers’ or ‘non-improvers’, while
the present study's comparison consisted of outcome in people
receiving CBTp+SC versus SC. We earlier reported (Premkumar
et al., 2009) that CBTp+SC responders had larger posterior hippo-
campal volume than CBTp+SC non-responders, which given that
greater hippocampal volume is related to better learning and
memory in schizophrenia patients (Antonova et al., 2004; Nestor
et al., 2007; Rametti et al., 2007), is consistent with the Penades
et al. study ﬁndings. Speciﬁc measures of cognitive control and
self-versus-other discrimination may also be more relevant to CBTp
response (Kumari et al., 2009; Kumari et al., 2010). Future studies
may also examine whether pre-therapy neuropsychological mea-
sures related to cognitive insight, such as the meta-cognition task
(Lysaker et al., 2009), are related to symptom improvement
following CBTp. We also did not observe the effect of gender or
duration of illness on symptom improvement that has been
previously reported (Tarrier et al., 1998; Brabban et al., 2009). It
is possible that gender effects may be speciﬁc to certain CBTp
formats, as women responded better to brief CBTp (6 sessions over
3 months) than men (Brabban et al., 2009), and duration of illness
may predict CBTp when therapy is combined with coping skills
enhancement (Tarrier et al., 1998).
4.2. Changes in clinical status following CBTp
The levels of depression and self-esteem and, at a near signiﬁcant
level, self-certainty improved to a greater extent in the CBTp+SC
than SC control group, in addition to PANSS symptoms. Our ﬁndings
support a number of studies demonstrating signiﬁcant improvements
in depression (Garety et al., 2008; Peters et al., 2010) and increased
self-esteem (Gumley et al., 2006). Although self-certainty did not
predict CBTp responsiveness, possibly because such an association
may be observed in patients with a greater level of delusions (Brabban
et al., 2009), it somewhat improved following CBTp in the present
study. CBTp may help patients to refrain from overconﬁdence in their
beliefs and inferences of anomalous experiences regardless of the
presence of delusional beliefs.
4.3. Limitations and future research
The moderate sample sizes of the CBTp+SC and SC control groups
may not have allowed sufﬁcient power to demonstrate signiﬁcant
group differences in the pre-therapy coping-symptom improvement
relationships. This study, like most studies on coping strategies in
psychosis (Phillips et al., 2009), used a relatively small number of
outpatients who mostly had a paranoid schizophrenia diagnosis. This
sample represents a relatively stable population of patients who have
greater access to social and community-based systems than would
their inpatient counterparts, and may use different coping strategies
to inpatients (Phillips et al., 2009). Further research is needed to test
this possibility. In addition to patients with schizophrenia, CBTp is
found to be effective in patients in the early initial prodromal state of
the pre-psychotic phase (Morrison et al., 2004; Bechdolf et al., 2005).
Future research should also analyse the role of cognitive insight and
coping in the efﬁcacy of CBTp in pre-psychotic phase.
361P. Premkumar et al. / Psychiatry Research 187 (2011) 354–362The CBTp+SC group had greater pre-therapy cognitive insight,
general IQ and verbal skills than the SC control group at baseline,
which may have contributed to their better outcome, and confounded
the pre-therapy cognitive insight-symptom change correlations. It is
unlikely that the CBTp groupwould have improved to the same extent
without CBTp over the course of this study, but it is possible that the
SC control group would show less improvement with CBTp when
offered as a result of lower pre-therapy level of insight. A greater
number of drop-outs in the SC control, than CBTp+SC, group may
also have led to a bias in some of the ﬁndings.
4.4. Conclusions
Coping styles and cognitive insight before therapy play a role in
determining CBTp efﬁcacy in patients with schizophrenia, speciﬁcally
for negative and general symptoms. Being able to reﬂect on one's
psychotic experiences and reappraise misinterpretations while
refraining from being overconﬁdent about one's interpretations, as
well as having coping strategies, especially planning and active
coping, are related to better CBTp responsiveness.
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